Category: Pharma

TIENS Group Initiates Post-Pandemic Forum on Global Health

TIENS Group hosted the One Belt One Road: Health Industry Development Forum for the Post-Pandemic Era on August 3, 2021.

The forum acted as a platform for industry leaders and stakeholders from different sectors to meet up and delve into health industry challenges, addressing them in turn for the post-pandemic era.

Later, the guests debated innovation, reform and improvement in the global health industry. China, which has become a stern yet exemplary leader in the world’s post-pandemic era, is leading the movement of change in the health industry. Global health sectors, especially in Asia, have benefited greatly from China’s supply chain model and the innovation brought about by the Belt and Road Initiative.

TIENS Group plays a representative role in China’s health care industry, a major reason for its steady growth. Li Jinyuan, Chairman of TIENS Group, delivered the hallmark mentioning design and efficiency in the health industry today and spoke of his Group’s endeavours and the support they have received from Chinese Belt and Road policy. A strong advocate of the Belt and Road Initiative, TIENS Group makes no secret of this progress helping them.

The global progress of Chinese enterprises means keeping abreast of the times. TIENS Group enjoys an excellent reputation in today’s market and proudly carries the “Made in China” label on all its great health products. Currently, its business has expanded to Europe, Asia, Germany, Russia, Africa, and other regions around the globe. The Group has its own logistics in many countries as it covers the world through its own expanding operations.

TIENS Group has been engaged in the larger health industry for 26 years. It has accumulated profound experience in the domestic and foreign markets, setting up solid supply channels, accumulating growing numbers of customers, and building a well-known brand. As a result, it holds the balance in the health industry both at home and abroad.

The TIENS Group aims to strengthen its exchange and cooperation with domestic and foreign enterprises over this broad platform, jointly promoting the development of the health industry with others, and making a greater contribution to the health of the world’s citizenry. Please visit the company’s website at https://www.tiens.com/.

Media contact:
Yukai Wang, TIENS Group
E: zcfw@tiens.com
U: https://www.tiens.com/

SOURCE: TIENS Group

Following Series A Financing, Scivita Medical Completes Series B Financing of Nearly RMB0.4 Billion to Accelerate the Strategic Layout of Globalization

Following the completion of series A round financing, with the acceleration of the research and development and commercialization of endoscopy product, Scivita Medical Technology Co., Ltd. (Scivita Medical) announced today that it has received nearly RMB0.4 Billion in Series B financing, with new investors such as Hudson Bay Capital Management and Prime Capital, as well as continuous support from existing shareholders such as GL Ventures, Lilly Asia Ventures and Matrix Partners China.

This round of financing will continue to be used for research and development, capacity expansion, and domestic and international commercialization of innovative products in endoscopy and related fields.

Since its inception, Scivita Medical has taken globalization as an important strategy and has set up R&D centers in Suzhou, China and Tokyo, Japan to promote simultaneous global R&D, patent application, registration and commercialization of its products, and strives to building a global leading platform for innovative products in endoscopy and related fields. The successful completion of this round of financing fully reflects the recognition of the new investors and the existing shareholders for the future development potential and the expectation of the sustainable development of Scivita Medical.

Driven by factors such as the promotion of graded treatment, the development of minimally invasive surgery and the aging population, the market demand and configuration rate of endoscopes are rising rapidly. Scivita Medical has a comprehensive product line covering both rigid and flexible endoscopes, reusable endoscopes, single-use endoscopes, white light endoscopes, fluorescent endoscopes, etc. Currently, Scivita Medical’s commercialized products include3D Visualization System, 4K UHD Camera System, 4K-3D Camera System, 4K Sinoscope, 4K Arthroscope, Single-use Hystero Videoscope, Single-use Urology Videoscope, Single-use Broncho Videoscope, etc. In the future, Scivita Medical will continue to launch new products while promoting the simultaneous certification of related products in China, the United States, Japan, Europe and other countries and regions, and continue to promote the products to the global market.

Scivita Medical’s innovation has been ahead of the market with industry leading position, which reflects Scivita Medical’s R&D strength and confidence. Scivita Medical has global cutting-edge technologies, including ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology(including monocular 3D and binocular 3D), single-use technology, special light visualization technology (such as fluorescence visualization), and ultra-fine endoscopic technology. In the future, Scivita Medical will also integrate the existing technologies to form a diversified product matrix such as 4K fluorescence and 3D fluorescence.

Scivita Medical aims at solving clinical pain points through technological innovation and developing high quality products that suit the needs of clinicians. For example, in the development process of4K UHD visualization, through cooperation between medical staff and the industry, Scivita Medical learned the pain points in laparoscopy such as “endoscope fogging” or “smoke interference”, and successfully developed the lens tip heating feature, effectively avoiding fogging caused by temperature differences. The signal processing technology enables the one-key fogging removal function on the camera, which effectively removes smoke interference and improve the efficiency of surgery. In addition to effectively solving the problem of cross-contamination, the single-use endoscopes independently developed by Scivita Medical also enables the image quality to reach the standard of reusable endoscope. In addition, Scivita Medical has fully considered the ergonomics in product development process, and its single-use endoscopes not only allow clinicians to control flexibly with both left and right hands, but also meet the needs of clinicians in different scenarios of standing or sitting diagnosis, effectively alleviating clinicians’ operational fatigue and improving diagnosis and treatment efficiency for the benefit of more patients.

In terms of imaging clarity, color reproduction, or operability, conductivity, and insertion of endoscope, the clinical evaluation of Scivita Medical’s products have reached the international first-class level. In the past few years, most of the terminal hospitals where Scivita Medical’s products are sold in China are the tertiary hospitals represented by domestic tertiary Grade A hospitals, and the products are on par with major international brand products in terms of product quality and effect. In the future, in addition to insisting on the strategic goal of making high-end Made-in-China products, Scivita Medical will also launch generic endoscope systems for hospitals at all levels, and benefit hospitals at all levels with products of international leading level.

In the future, Scivita Medical will continue to implement the strategy of globalization, deepen its focus on clinical needs and pain points, and work together with global clinical experts to promote the development of the endoscopy industry and enhance the level of safety, effectiveness and accuracy of treatments, thereby benefiting patients around the world.

From Red Gold to Olympic Gold: Seedo Corp. Seeks Solutions for Athletes and More

Seedo Corp. (http://saffron-tech.ag) (OTC: SEDO), an agtech company that is developing the protocols to grow saffron using vertical farming technology, today announced that it is expanding its research to include the study of the spice’s well known natural anti-anxiety and antidepressant properties. Similar to the approach of the indoor cannabis industry, Seedo hopes to be able to enhance the medicinal properties of this unique herb for use in pharmaceutical and nutraceutical applications. Mental health has come to the forefront in sports with Simone Biles withdrawing from the Tokyo Olympics and Naomi Osaka opting out of the French Open and Wimbledon. With mental health entering the cultural conversation, Seedo Corp. hopes saffron will be seen as part of a new nature-based approach to mental health.

Simone Biles

“The timing is right to leverage saffron’s potential medicinal properties and create new applications that could address the recent paradigm shift regarding mental health,” says David Freidenberg, CEO. “Seedo Corp is committed to developing breakthroughs rooted in nature that are effective and safe for athletes and everyday consumers alike.”

“Until recently, the options for treating depression and anxiety were quite limited,” says Dr. Nizan Primor, CEO, Naveh Pharma, a company that specializes in creating pharmaceutical and healthcare products with unique active ingredients including saffron. “A recent study (https://pubmed.ncbi.nlm.nih.gov/31118846/) found that taking 28 mg of saffron daily was just as effective as Fluoxetine, Imipramine, and Citalopram — conventional treatments for depression.”

A fascinating study was published in the Journal of Adolescent Psychopharmacology (https://pubmed.ncbi.nlm.nih.gov/30741567/) which explicitly found that saffron extract has the same efficacy as Ritalin in improving focus for children with ADHD, suggesting there is a promising future in developing new natural therapies to treat these common ailments. In another recent study by the Journal of Psychopharmacology (https://journals.sagepub.com/doi/abs/10.1177/0269881119867703) it was discovered that patients who were administered saffron extract for eight weeks saw “a greater improvement in depressive symptoms.”

Seedo Corp successfully harvests saffron using vertical farming technology. Seedo Corp hopes to expand the billion dollar saffron market by producing a reliable, consistent and large-scale supply of the spice.

About Seedo

Seedo Corp. (OTC: SEDO) is an agtech company that focuses on the research, development, and commercialization of agriculture products that are high in demand but are hindered by the low yields and specifications required by traditional farming. Seedo’s technology is aimed at offering a responsible and sustainable way to grow crops in a world confronted by environmental challenges and dwindling earth reserves, diminishing water sources and unstable weather conditions.

Cautionary Note Regarding Forward-Looking Statements

This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our ability to successfully execute a smooth transition of CFO functions as well as our ability to retain and recruit qualified executives; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; our ability to successfully compete in the marketplace; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Reports on Form 10-Q and in our Annual Report on Form 10-K, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Contact:
David Freidenberg,
Chief Executive Officer
info@saffron.ag
+1 (800) 608-6432

ClinTex (CTi) Launches CTi-OEM Blockchain Clinical Trial App

The ClinTex (CTi) tokenized platform (clintex.io) will be the first of its kind to utilize blockchain-based clinical data analytics to address the main causes of clinical trial inefficiency, helping to drive down the cost of new medicines and expediting their delivery to patients.

ClinTex (CTi) launches ‘Operational Excellence Module’ (CTi-OEM) – a blockchain clinical trial application to tackle clinical trial inefficiencies and high costs. (ClinTex)

The initial spark of an idea that would eventually become ClinTex started in 2014, at the DIA Forum in Vienna. By 2018, Clintex was formally working on the Clinical Trials Intelligence (CTi) platform. CTi’s purpose is to deliver data analysis at scale, to drive collaboration and insights across clinical trials.

With large pharma companies like Merck and Novartis already testing blockchain as a technology of the future to support their clinical trial strategy for patient information and to manage clinical trial medication, this paves the way for ClinTex CTi to partner with the industry to deliver more innovative and impactful uses of blockchain to increase clinical trial efficiency.

The CTi-OEM App
Leveraging 50+ years of medicine development experience, ClinTex has moved at a breakneck pace to launch its first blockchain clinical trial app of the CTi Platform, the Operational Excellence Module (CTi-OEM). CTi-OEM provides intuitive operational oversight of clinical trials for clinical project managers, clinical data managers and remote staff; allowing in-stream decision-making on what actions are required to ensure a successful investigation into the safety and efficacy of new medicines.

Using the CTi-OEM console, researchers can deep dive into clinical trial data and take proactive action to make clinical trials run more efficiently. These operational issues include things like clinical protocol deviations and adverse events relating to patient safety in the clinical trial.

The company has prioritized the development of the CTi-OEM blockchain clinical trial app to target some of the major causes of inefficiency in clinical trials, enabling its first app to derive maximum tangible benefits for the pharma and clinical trials industry. CTi-OEM achieves this through a comprehensive portfolio of tools, which is accessible through the CTi-OEM console.

Compliance Requirements & Patient Safety
One of the major obstacles to a successful clinical trial is adherence to the clinical trial protocol. Analytics within the CTi-OEM application allows the detection and analysis of these deviations and allows the clinical trial team to take speedy action. These tools provide powerful insights into the major causes of non-compliance in clinical trials providing analytics to help clinical trial teams identify and resolve them to speed up progress.

Protecting patient safety during a clinical trial is the most important aspect in the development of any new medicine. Adverse events are safety issues that occur during the testing of a new medicine. CTi-OEM provides valuable insight into patient safety throughout a clinical trial. For example, adverse event rate per site allows the clinical trial team to identify those sites that have a high rate of safety events which may point to procedural problems or may also uncover safety risks that need further investigation.

These are just a few examples of CTi-OEM’s toolkit. For more information on CTi-OEM, there is a series of demonstration videos that give an overview of the platform, and how it can help alleviate pain points in clinical trials. Any clinical trial professionals interested in learning more or becoming early adopters can email ClinTex at industry@clintex.io or visit http://clinicaltrialsintelligence.org.

CTi-OEM is just the beginning for ClinTex offerings. Eventually, the platform will consist of 7 different blockchain clinical trial applications that derive intelligent analytics from all types of clinical trial data, and it is these analytics that can be used to drive efficiency in clinical trials. The ClinTex roadmap is on track to have live client onboarding and revenue generation by the end of 2022.

ClinTex Socials
Twitter : https://twitter.com/ClinTexCTi
Telegram : https://t.me/ClinTexCTi
Medium : https://medium.com/clintexcti
YouTube : https://youtu.be/iK3zkhsDzzA
Website : https://clintex.io/

Media Contact Details
Contact Email: press@clintex.io

About ClinTex
ClinTex CTi (Clinical Trials Intelligence) is a solution provider to the pharmaceutical industry, a new type of software platform aimed at transforming the medicine development industry through the application of predictive analytics, machine learning, and the novel use of blockchain technology and smart contracts in clinical trials. Our mission is to bring down the cost of medicine and improve the speed to market of new medicines for the people who need them, through vastly reducing development costs for the global pharmaceutical industry.

Legend Capital invests in Series A funding round of BioMap, a biological computing platform

BioMap, a biological computing platform enterprise, has recently completed the Series A funding round worth over a hundred million US dollars, which Legend Capital participated in. The funds will be used to for R&D and talent recruitment.

BioMap is positioned as an innovative medicine R&D platform driven by a biological computing engine. It was co-founded by Robin Li in November 2020 and he currently serves as the Chairman. Through advanced computing and biotechnology, BioMap draws maps on disease targets and drug design to realize the Global First-in-class original drugs. In the future, BioMap will also focus on the field of the immune mechanisms of tumors, autoimmune diseases and fibrotic diseases.

Richard Li, the President of Legend Capital, said: “It is our second cooperation with Baidu this year after the investment in Baidu’s AI chip unit Kunlun in March. We hope to continue to maintain close cooperation with Baidu in the field of scientific and technological innovation in the future. We take a positive long-term view of the integration of IT and life science and technology. BioMap empowers life science with AI, and accelerates the R&D of new drugs and diagnostic products through the integration and innovation of AI technology and cutting-edge biotechnology. In the future, Legend Capital hopes to realize the full potential of the advantages of our enterprise ecosystem in the field of healthcare, and promote BioMap’s cooperation with leading companies in related fields, so as to provide intelligent computing platform support for the healthcare industry, give impetus to industrial upgrading and benefit more patients. “

Legend Capital has been focusing resources to research the deep integration of the healthcare industry and technology. In recent years, it has continued to explore the field of medical AI. In addition to BioMap, Legend Capital has also invested in AI microbial pharmaceutical company Xbiome, AI innovative drug development platform StoneWise, AI medical image assisted diagnosis company Deepwise, Lunit, AI medical pathology diagnosis company Deep Informatics, gene big data company Genowis, AI medical chronic disease management system company Ayshealth Technology, etc.

Singapore cord blood bank Cryoviva establishes footprint in the UAE

Family cord blood bank Cryoviva Singapore is pleased to announce that it has made a successful foray into the UAE market in line with its strategic growth plans. After 7 years of serving young families in Singapore, the expansion into Dubai and the other Emirates in the UAE is an important milestone for Cryoviva.

Rajesh Nair, CEO of Cryoviva Singapore

“This is an important step in our journey, fulfilling our mission to give every family the chance to benefit from the medical potential of cord stem cells should they need it. That we have been able to attract young families in the UAE to trust us with their baby’s precious cord blood is not only a testament to our credentials as a company, but also to Singapore’s reputation for world-class facilities and strict adherence to high-quality standards. We invite healthcare providers offering maternity services to collaborate with us to provide even greater service to their valued patients,” said Rajesh Nair, CEO of Cryoviva Singapore.

“While we continue with our growth efforts in several other countries – both in the ASEAN region as well as in the Middle East, I would also like to reiterate our commitment to serving families in Singapore. We believe that there is still considerable potential for family cord blood banking services to grow in a developed and discerning market like Singapore. We also look forward to contributing to further our city’s position as a great destination to avail of world-class healthcare services.”

About Cryoviva Singapore

Established in 2014, Cryoviva (https://cryoviva.com.sg) is a well-regarded family cord blood bank in Singapore. The company is part of an international group backed by multinational investors. The Cryoviva group has successfully stored over 160,000 cord blood units. Cryoviva’s cord blood storage facility in Singapore is MoH-licensed, AABB accredited and IS ISO 9001:2015 QMS Certified, testaments to the stringent processes and quality standards that it adheres to. With its central location and proximity to most major maternity hospitals in Singapore, cord blood samples reach our facilities quickly and efficiently to ensure top quality maintenance upon storage.

Media Contact:
Krish Sharma, General Manager
Cryoviva Singapore,
Tel: +65-9651 7080
E-mail: krish@cryoviva.com.sg

Sri Trang Group accelerates Covid inoculation program

As the Sri Trang Group races towards its goal of 100%, highlighting  commitment to staff welfare and ESG to achieve business sustainability

Pressing ahead with its campaign to provide inoculation to all Southeast Asia based employees of the Sri Trang Group of Companies against Covid-19 with Sinopharm vaccine, provided by the Chulabhorn Royal Academy, Sri Trang Gloves (Thailand) PCL (SET: STGT) reached its goal of 100% jabs for its entire workforce of 11,000 employees in production plants and Southeast Asia offices.

The second jabs will be given at the end of July. Other companies in the group will continue their inoculation programs where permitted until the goal is achieved, demonstrating the group’s commitment to employee welfare.

Most recently, Veerasith Sinchareonkul, Executive Director of Sri Trang Agro-Industry PCL (STA), and Jarinya Jirojkul, CEO of Sri Trang Gloves (Thailand) PCL, pledged to implement the group’s ESG policy, which pays special attention to sustainability in business while treating employees with fairness in accordance with human rights and transparency principles. The companies have launched the Covid-19 vaccination program for all Southeast Asia based employees and their family members as well as select employees of suppliers and trading partners.

At the same time, the Sri Trang Group will earnestly continue to acquire additional doses of alternative vaccines for its employees and families in Thailand and abroad, as well as select members in its supply chain, to build confidence for all concerned and to help these countries overcome the current Covid-19 crisis as soon as possible.

For more information, visit Sri Trang Gloves (Thailand) PCL at https://www.sritranggloves.com/en.
Released by Public Relations Dept., MT Multimedia Co., Ltd. for Sri Trang Gloves (Thailand) PCL
Wasana “Jeab” Wongsiri, Tel: +66 84 359 0659, wasana.w@mtmultimedia.com
Sri Trang Gloves (Thailand) PCL (SET: STGT) (SGX: STGT)
Sri Trang Agro-Industry PCL (SET: STA) (SGX: STA)

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

First Launch For Dayvigo In Asia Outside Of Japan

Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan.

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.

DAYVIGO binds to orexin receptors OX1R and OX2R and acts as a competitive antagonist with stronger inhibition effect on OX2R, which suppresses both REM and non-REM sleep drive, such that DAYVIGO may provide faster sleep onset and better sleep maintenance to patients.

DAYVIGO was launched in the U.S. and Canada for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance; and in Japan for the treatment of insomnia. In addition, applications for approval have been submitted to the respective regulatory authorities in Australia, Brazil, India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan and Thailand, and Eisai plans to further expand submissions of applications for approval in other countries.

Insomnia is characterized by difficulty falling asleep, staying asleep or both, despite an adequate opportunity to sleep, that can lead to daytime consequences, such as fatigue, difficulty concentrating and irritability.1,2 Insomnia is one of the most common sleep-wake disorders. It is estimated that approximately 30% of adults worldwide have symptoms of insomnia.3,4 In Hong Kong, over 35% of adults are reported to have symptoms of insomnia.5 In particular, older adults also have a higher prevalence rate with many experiencing insomnia symptoms for months to years. As a result, insomnia causes various social losses, such as long absences and reduced productivity. It can increase the risk of falls in older adults. 6

Eisai will continue its efforts to deliver DAYVIGO as a new treatment option to insomnia patients across the world with the hope of contributing to restoration of daytime function and recovery for patients with insomnia by potentially delivering an active daytime life through fast sleep onset and good quality sleep.

About DAYVIGO (Generic Name: Lemborexant)
DAYVIGO, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of DAYVIGO to orexin receptors may influence DAYVIGO’s potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects.

About Sleep-Wake Disorders and Insomnia
Sleep-wake disorders consist of disease categories such as insomnia, Irregular Sleep Wake Rhythm Disorder (ISWRD), hypersomnia and breathing-related sleep disorders. Among the sleep-wake disorders, insomnia is the most common with persistent insomnia symptoms experienced by approximately 30% of the adult population worldwide.(3),(4) Insomnia disorder is characterized by difficulty falling asleep, staying asleep or both, despite an adequate opportunity to sleep, which can lead to daytime consequences, such as fatigue, difficulty concentrating and irritability.(1),(2)

Sleeping well is essential for good health, including brain health.(7) Studies suggest an optimal sleep duration between seven and eight hours.(8) Poor sleep is associated with a wide range of health consequences, including an increased risk of hypertension, accidental injury, diabetes, obesity, depression, heart attack, stroke, dementia and adverse effects on mood and behavior.(1),(8)

Women are 1.4 times more likely than men to suffer from insomnia.(9) Older adults also have higher prevalence of insomnia as aging is often accompanied by changes in sleep patterns, including disrupted sleep, frequent waking, and early waking, that can lead to less sleep time.(10)

About the Anti-Insomnia Drug Market in Hong Kong
The anti-insomnia drug market in Hong Kong as of 2020 valued at approximately 8.4 million USD, comprising nearly 9% of the insomnia drug market in Asia (Hong Kong, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand).(11)

(1) Ferrie JE, et al. Sleep epidemiology – a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10.
(3) Institute of Medicine. Sleep disorders and sleep deprivation: An unmet public health problem. Washington, DC: National Academies Press. 2006.
(4) Ohayon MM, et al. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97-111.
(5) Wong, et. al. Prevalence of Insomnia among Chinese adults in Hong Kong: a population-based study. J Sleep Res. 2011; 20: 117-126
(6) National Institute of Public Health. Sleep disorders practice guidelines – for the proper usage of sleeping medications and the withdrawal: insomnia medical manual aiming for breaking through (available in Japanese only).
(7) Cappuccio FP, et al. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585-592.
(8) Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017;89(12):1244-1250.
(9) Roth T, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, tenth revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, second edition criteria: results from the America Insomnia Survey. Biol Psychiatry. 2011;69:592- 600.
(10) Crowley K. Sleep and sleep disorders in older adults. Neuropsychol Rev. 2011;21(1):41-53.
(11) Copyright 2021 IQVIA.Internal analysis based on IQVIA Analytics Link 2020. Reprinted with permission.

Avantor Named Best Company in Bioprocessing Excellence for Single-use Solutions and Best Bioprocessing Supplier for Upstream Processing at Biologics Manufacturing Korea 2021

Avantor, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies and applied materials industries, was named best company in bioprocessing excellence for single-use solutions and best bioprocessing supplier for upstream processing at Biologics Manufacturing Korea (BMK) 2021.

This is the second consecutive year Avantor has been selected as the best company in the single-use category at BMK. As the development and supply of biopharmaceuticals, including COVID-19 vaccines and therapeutics, become more important than ever, Avantor has been actively supporting the discovery to delivery of biopharmaceutical therapies to both domestic and foreign pharmaceutical companies. A key piece of this contribution is supplying differentiated upstream solutions such as high-purity materials.

Avantor also has been recognized for its ongoing efforts to develop single-use solutions, which are emerging as the preferred option to improving biopharmaceutical manufacturing processes. Avantor is responding to rapidly increasing needs for treatments and therapies by providing customized solutions to biopharma companies. Avantor closely analyzes manufacturing processes to support customers with increased yield and reduced resources when developing new therapeutics.

SK Lee, Sales Director of Avantor Korea & Japan, said, “We are extremely proud to be recognized by BMK for our leadership in bioprocessing development by providing solutions to biopharmaceutical manufacturers. Working closely with our customers, we play a critical role in enabling breakthroughs in life-changing biologics.”

Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for Avantor said, “Avantor’s continued investment in single-use solutions, including our recent acquisition of RIM Bio, with manufacturing capabilities in China, go a long way to demonstrate our commitment to delivering bioprocessing excellence. Our process development and optimization capabilities carried out by our dedicated expert researchers at our Korea Innovation Center is helping customers deliver on cost and time efficiencies.”

For more information on Avantor’s single-use solution for biopharmaceutical manufacturing, visit https://youtu.be/mfjZEfO_RVM.

About Avantor

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For information, visit and find us on LinkedIn, Twitter and Facebook.

About Biologics Manufacturing Korea Excellence Award 2021

The Biologics Manufacturing Korea Excellence Award seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality. 2021 marks the tenth year of ABEA. The BMK Awards is part of the Asia-Pacific Bioprocessing Excellence Awards (ABEA) which seeks to recognize organizations within Korea who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in biological products manufacturing.

AMEA Media Contact
Christina Koh
Director – Communications, AMEA
Avantor
Phone: +65 9170 0169
Email: Christina.Koh@avantorsciences.com

Cofttek Announces Mass-Production and Supply of Urolithin A & B

Cofttek Holding Limited, a Chinese pharmaceutical manufacturer, will mass-produce and supply the latest Urolithin A & B product to dietary supplement companies from June 2021.

With 5 years of research into ellagitannins, the source of urolithins, Cofttek is the only pharmaceutical facility in the world able to mass-produce Urolithin A & B.

Following 5 years of research, Cofttek has become the only facility in the world able to mass-produce Urolithin A & B. (Cofttek.com)

Urolithin A possesses anti-inflammatory, anti-oxidant, anti-cancer, hypoglycemic and other biological properties. Urolithin A can improve the quality and function of mitochondria, and increase the strength and endurance of ageing muscles. Urolithin B has anti-inflammatory and antioxidant properties and is also a regulator of skeletal muscle mass.

Studies have shown Urolithin A & B in combination can be used in treating intervertebral disc degeneration (IDD), Alzheimer’s and dementia-related disorders, and other diseases. After 5 years of technical research, Cofttek’s production capacity of Urolithin A & B now exceeds 2000 kg/month – the only biochemical firm worldwide to have achieved mass production.

About Urolithin
Urolithins are secondary metabolites of ellagic acid derived from ellagitannins. Ellagitannins are converted by the human gut microflora into ellagic acid which is further transformed into urolithins A, urolithin B, urolithin C and urolithin D in the large intestines. Know more at https://www.cofttek.com/products/urolithin/

About Cofttek
Cofttek Holding Limited, founded in 2008, is a high-tech pharmaceutical biochemical enterprise, integrating production, R&D and sales. It is located in Luohe Chemical Industry Park, Luohe City, Henan Province, and is committed to the research and development of advanced pharmaceuticals, providing innovative products and high-quality services for the pharmaceutical industry.

Media Contact:
Dr. Zeng, Cofttek Holding Limited
E: info@cofttek.com, T: +86 1390 2465871
Website: https://www.cofttek.com

SOURCE: Cofttek Holding Limited